Target intelligence / Profile preview

Ferredoxin 1 (FDX1)

Target
FDX1
Molecular classification
Iron–sulfur protein, Electron transfer protein, Mitochondrial protein, Enzyme cofactor
01

Overview

Ferredoxin 1 (FDX1) is a mitochondrial iron–sulfur protein that functions as an electron carrier, transferring electrons from ferredoxin reductase (FDXR) to various mitochondrial enzymes[1][3]. It contains a [2Fe-2S] iron–sulfur cluster, is highly conserved, and plays major roles in steroid hormone synthesis, bile acid and vitamin D metabolism, TCA cycle enzyme lipoylation, and iron–sulfur cluster biogenesis[1][3][6]. FDX1 is vital for lipid homeostasis and embryonic development; knockout in mice causes embryonic lethality and metabolic disorders, while partial loss leads to lipid accumulation and liver disease but not spontaneous tumors[1]. FDX1 also participates in the regulation of cuproptosis, a form of copper-dependent cell death[1]. It does not act as a direct drug target in current therapeutics, but its role in essential metabolic pathways and disease phenotypes makes it a protein of interest for future drug discovery and biomarker studies[1][3].

Other names
AdrenodoxinMitochondrial ferredoxin 1Human mitochondrial ferredoxin 1
02

Mechanism of action

Electron transfer to mitochondrial cytochrome P450 enzymes for steroid, bile acid, and vitamin D synthesis Support of iron–sulfur cluster assembly enzymes

03

Biological functions

Electron transportIron–sulfur cluster biogenesisSteroid hormone biosynthesis (steroidogenesis)Vitamin D metabolismBile acid synthesisLipoylation of tricarboxylic acid (TCA) cycle enzymesRegulation of lipid metabolismRegulation of cuproptosis (copper-induced cell death)
04

Disease associations

CancerLipid metabolism disorders (e.g., fatty liver/steatohepatitis)Embryonic lethality when deficient
05

Safety considerations

Essential for embryonic development—complete inhibition may cause lethalityDisruption induces metabolic dysfunction, such as steatohepatitisDeficiency may alter steroidogenesis and energy metabolism in liver and endocrine organs
06

Interacting drugs

None confirmed as approved drugs; however, inhibitors/modulators of enzymes that depend on FDX1 may indirectly interact
07

Biomarkers

FDX1 expression/activity as a potential biomarker for tumors with altered steroidogenesis or lipid metabolismCandidate biomarker for sensitivity to cuproptosis-inducing agents

Beyond the preview

Go deeper on Ferredoxin 1 (FDX1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ferredoxin 1 (FDX1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call